Rachel Swart

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

Daruka Mahadevan, Laurence Cooke, Christopher Riley et al. · Oncogene · 2007 · 277 citations

Imatinib Resistance, Chromatin, Oncology +8

Latent Membrane Protein 2A-Mediated Effects on the Phosphatidylinositol 3-Kinase/Akt Pathway

Rachel Swart, Ingrid K. Ruf, Jeffery T. Sample et al. · Journal of Virology · 2000 · 151 citations · Full text

Tyrosine 112 of Latent Membrane Protein 2A Is Essential for Protein Tyrosine Kinase Loading and Regulation of Epstein-Barr Virus Latency

Sara Fruehling, Rachel Swart, KristIne M. Dolwick et al. · Journal of Virology · 1998 · 133 citations · Full text

GLI Activates Transcription through a Herpes Simplex Viral Protein 16-Like Activation Domain

Joon Won Yoon, Jian Yang, Rachel Swart et al. · Journal of Biological Chemistry · 1998 · 89 citations · Full text